Product logins

Find logins to all Clarivate products below.


Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the birth incidence and prevalence of CF for each country, as well as annualized case counts projected to the national population.

Clarivate’s Epidemiology’s CF forecast will answer the following questions:

  • How will improvements in survival change the number of people living with a diagnosis of CF?
  • Of all people diagnosed with CF, how many in each country are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CF over the forecast period?

All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate’s Epidemiology forecasts the following CF patient populations:

  • Birth incident cases.
  • Diagnosed prevalent cases.
  • Diagnosed prevalent cases stratified by CFTR mutation.
  • Diagnosed prevalent cases stratified by FEV1 status.
  • Diagnosed prevalent cases stratified by airway pathogen.
  • Drug-treated prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Geographic Focus: China – COPD – China In-Depth (China)
COPD is a progressive respiratory condition that primarily affects adults, particularly smokers and individuals exposed to environmental pollutants. The COPD therapeutics market in China includes a…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…